Orchestra BioMed Holdings (OBIO) EBITDA (2021 - 2026)
Orchestra BioMed Holdings (OBIO) reported EBITDA of -$20.8 million for Q1 2026, down 10.77% year-over-year from -$23.3 million in Q1 2025, and down 432.12% on a QoQ basis from $6.3 million in Q4 2025.
Orchestra BioMed Holdings (OBIO) has 6 years of EBITDA data on file, last reported at -$20.8 million in Q1 2026.
- Quarterly EBITDA fell 10.77% year-over-year to -$20.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$54.7 million (up 17.44% YoY) and the FY2025 annual result came in at -$52.7 million, up 13.56% from the prior year.
- EBITDA declined to -$20.8 million in Q1 2026 per OBIO's latest filing, from $6.3 million in the prior quarter.
- Across five years, EBITDA topped out at $6.3 million in Q4 2025 and bottomed at -$20.8 million in Q3 2025.
- The 5-year median for EBITDA is -$13.3 million (2023), against an average of -$12.8 million.
- The widest annual swing landed in 2022, when EBITDA plunged 10786.76%; it then surged 138.64% in 2025.
- Tracing OBIO's EBITDA over 5 years: stood at -$9.8 million in 2022, then plunged by 30.67% to -$12.8 million in 2023, then fell by 27.06% to -$16.2 million in 2024, then surged by 138.64% to $6.3 million in 2025, then plunged by 432.12% to -$20.8 million in 2026.
- Per Business Quant, the three latest OBIO EBITDA figures stand at -$20.8 million (Q1 2026), $6.3 million (Q4 2025), and -$20.8 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -13.63 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -14.44 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 661.60 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 201.19 Mn |
| 10 | Orchestra BioMed Holdings | 245.24 Mn | 255.02 Mn | 78,000.00 | -20.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -20.79 Mn |
| Dec 31, 2025 | 6.26 Mn |
| Sep 30, 2025 | -20.80 Mn |
| Jun 30, 2025 | -19.38 Mn |
| Mar 31, 2025 | -18.77 Mn |
| Dec 31, 2024 | -16.20 Mn |
| Sep 30, 2024 | -15.31 Mn |
| Jun 30, 2024 | -16.00 Mn |
| Mar 31, 2024 | -13.46 Mn |
| Dec 31, 2023 | -12.75 Mn |
| Sep 30, 2023 | -13.30 Mn |
| Jun 30, 2023 | -12.11 Mn |
| Mar 31, 2023 | -10.97 Mn |
| Dec 31, 2022 | -9.76 Mn |
| Sep 30, 2022 | -10.28 Mn |
| Jun 30, 2022 | -7.85 Mn |
| Mar 31, 2022 | -5.73 Mn |
| Dec 31, 2021 | -92,045.00 |
| Sep 30, 2021 | -94,445.00 |
| Jun 30, 2021 | -96,318.00 |
| Mar 31, 2021 | -111,948.00 |